ArticleCancer prevention research (Philadelphia, Pa.)2011
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.Journal of the National Cancer Institute · 2026Article
- Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial.Contemporary clinical trials · 2024Article
- Review
- The value of imaging combined with clinicopathological features in the diagnosis of high-risk breast lesions.Gland surgery · 2022Article
- Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.Hormones & cancer · 2020Review
- Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens.Breast cancer (Tokyo, Japan) · 2019Article
- Gene expression signature of atypical breast hyperplasia and regulation by SFRP1.Breast cancer research : BCR · 2019Article
- NanoString-based breast cancer risk prediction for women with sclerosing adenosis.Breast cancer research and treatment · 2017Article
- Aromatase expression in atypical ductal hyperplasia in women.Breast cancer research and treatment · 2017Article
- Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.Cancer medicine · 2017Article
- How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?NPJ breast cancer · 2017Article
- Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.Oncology reports · 2016Article
- ERβ expression and breast cancer risk prediction for women with atypias.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2015Article
- Atypical hyperplasia of the breast--risk assessment and management options.The New England journal of medicine · 2015Article
- Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.Cancer prevention research (Philadelphia, Pa.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Estrogen receptor (ER) is expressed in normal and malignant breast epithelium, and expression levels have been found to increase with age in normal breast epithelium but not in atypical hyperplasia (AH) and carcinoma in situ. Here we assess ER expression in AH and its association with later breast cancer. ER expression was assessed immunohistochemically in archival sections from 246 women with AH who had open benign breast biopsy from 1967 to 1991. The ACIS III (Dako) was utilized to calculate ER expression in all atypical foci. Using multivariate linear regression, we examined associations of ER expression with age at biopsy, indication for biopsy, type of atypia, number of atypical foci, involution status, and family history. Breast cancer risk across levels of ER expression was also assessed compared with the Iowa SEER control population. Among 246 women, 87 (35%) had atypical ductal hyperplasia (ADH), 141 (57%) had atypical lobular hyperplasia (ALH), and 18 (7%) had both. Forty-nine (20%) developed breast cancer (median follow-up of 14.4 years). Multivariate analysis indicated that type of atypia and age at diagnosis were significantly associated with ER percent staining and intensity (P < 0.05). ER expression was increased in women with ADH and/or those over age 55. ER expression did not significantly impact breast cancer risk in patients diagnosed with atypia. We found increasing ER expression in AH with increasing age. ER expression in AH does not further discriminate breast cancer risk in women with atypia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.